Safety of aprotinin (again)

The Lancet

Volumn 372, Issue 9632, 2008, Pages 27-

  Casati, Valter ^a   Romano, Angelo ^a   D'Angelo, Armando ^b  

^a Anaesthesia and Intensive Care   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

APROTININ; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; TRANEXAMIC ACID;

BOVINE SPONGIFORM ENCEPHALOPATHY; DRUG SAFETY; HEART SURGERY; HUMAN; KIDNEY DISEASE; LETTER; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL;

EID: 46049090958     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)60983-6     Document Type: Letter

References (5)

1. Mouton R., Finch D., Davies I., Bincks A., and Zacharowski K. Effect of aprotinin on renal dysfunction in patients undergoing on-pump and off-pump cardiac surgery: a retrospective observational study. Lancet 371 (2008) 474-482
2. Hausenloy D., Pagano D., and Keogh B. Aprotinin-still courting controversy. Lancet 371 (2008) 449-450
3. Henry D., Moxley A., Carless P., et al. Anti-fibrinolytic use for minimising perioperative allogeneic transfusion. Cochrane Database Syst Rev 4 (2007) CD001886.
4. Casati V., Guzzon D., Oppizzi M., et al. Tranexamic acid compared with high-dose aprotinin in primary elective heart operations: effect on perioperative bleeding and allogeneic transfusions. J Thorac Cardiovasc Surg 120 (2000) 520-527
5. Casati V., Benussi S., Sandrelli L., et al. Intraoperative moderate acute normovolemic hemodilution associated with a comprehensive blood-sparing protocol in off-pump coronary surgery. Anesth Analg 98 (2004) 1217-1223